ATROVENT HFA Rx
Generic Name and Formulations:
Ipratropium bromide 17micrograms/inh; metered dose inhaler; CFC-free.
Boehringer Ingelheim Pharmaceuticals
Indications for ATROVENT HFA:
Bronchospasm associated with chronic bronchitis and emphysema.
2 inh 4 times daily; max 12 inh/day.
Allergy to atropine or its derivatives.
Not for primary treatment of acute attack. Avoid eyes. Narrow-angle glaucoma. GU obstruction. Pregnancy (Cat.B). Nursing mothers.
Caution with other anticholinergics.
Bronchitis, COPD exacerbation, dyspnea, headache, anticholinergic effects; paradoxical bronchospasm, hypersensitivity reactions.
Formerly known under the brand name Atrovent.
HFA (NO); soln (YES)
Inhaler—12.9g (200 inh); inhalation soln—contact supplier
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Nomophobia: The Modern-Day Pathology
- Emerging Theories in the Pathophysiology of MDD: Could the Opioid System Be Involved?
- Transdermal Nicotine Boosts Mood and Cognitive Function in Late-Life Depression
- Combination Cognitive Behavioral Therapy With Fluoxetine Effective for Adolescent Depression
- Prazosin May Be Effective as Treatment for Alcohol Use Disorder
- Text Message Reminders Improve Medication Adherence in Bipolar I Disorder
- Improving Medication Adherence in ADHD Lowers Risk for Oppositional Defiant Disorder, Conduct Disorder in Adulthood
- High Suicidality Among Children With ADHD Mediated by Family Functioning, Psychiatry Comorbidities
- Pilot Study Investigates Lithium vs Quetiapine for Bipolar Spectrum Disorder
- How Personalized Hospital Ratings May Drive Patient-Specific Care in the Digital Age